JP2024541940A5 - - Google Patents

Info

Publication number
JP2024541940A5
JP2024541940A5 JP2024525024A JP2024525024A JP2024541940A5 JP 2024541940 A5 JP2024541940 A5 JP 2024541940A5 JP 2024525024 A JP2024525024 A JP 2024525024A JP 2024525024 A JP2024525024 A JP 2024525024A JP 2024541940 A5 JP2024541940 A5 JP 2024541940A5
Authority
JP
Japan
Prior art keywords
retroviral vector
days
recombinant retroviral
item
vector according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525024A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024541940A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/047599 external-priority patent/WO2023076180A2/en
Publication of JP2024541940A publication Critical patent/JP2024541940A/ja
Publication of JP2024541940A5 publication Critical patent/JP2024541940A5/ja
Pending legal-status Critical Current

Links

JP2024525024A 2021-10-25 2022-10-24 治療剤またはワクチン送達のための組成物および方法 Pending JP2024541940A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163271675P 2021-10-25 2021-10-25
US63/271,675 2021-10-25
US202263413188P 2022-10-04 2022-10-04
US63/413,188 2022-10-04
PCT/US2022/047599 WO2023076180A2 (en) 2021-10-25 2022-10-24 Compositions and methods for therapeutic or vaccine delivery

Publications (2)

Publication Number Publication Date
JP2024541940A JP2024541940A (ja) 2024-11-13
JP2024541940A5 true JP2024541940A5 (https=) 2025-11-04

Family

ID=86158440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525024A Pending JP2024541940A (ja) 2021-10-25 2022-10-24 治療剤またはワクチン送達のための組成物および方法

Country Status (8)

Country Link
US (3) US11992524B2 (https=)
EP (1) EP4423288A4 (https=)
JP (1) JP2024541940A (https=)
KR (1) KR20240099340A (https=)
AU (1) AU2022377374A1 (https=)
CA (1) CA3235865A1 (https=)
TW (1) TW202334435A (https=)
WO (1) WO2023076180A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240099340A (ko) 2021-10-25 2024-06-28 젠비보, 인크. 치료제 또는 백신 전달을 위한 조성물 및 방법
CN116334009B (zh) * 2023-03-21 2026-04-24 广西大学 表达乙型脑炎病毒e蛋白的重组盖他病毒及其构建方法和疫苗应用
WO2025106748A1 (en) * 2023-11-15 2025-05-22 Genvivo, Inc. Compositions and methods for therapeutic delivery

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2452517A1 (en) * 2001-07-11 2003-01-23 University Of Miami Recombinant vsv for the treatment of tumor cells
EP2055316A1 (en) 2003-09-09 2009-05-06 VIRxSYS Corporation Lentivirus vector-based approaches for generating an immune response to HIV in humans
WO2006031996A2 (en) * 2004-09-14 2006-03-23 University Of Pittsburgh Of The Commonwealth System Of Higher Education Targeting viruses using a modified sindbis glycoprotein
US8329162B2 (en) * 2006-07-21 2012-12-11 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
RU2012140691A (ru) * 2009-03-13 2014-03-27 Лентиген Корпорейшен Вакцины на основе неинтегрирующегося ретровирусного вектора
RS53257B2 (sr) * 2009-07-24 2018-06-29 Immune Design Corp Lentiviralni vektori pseudotipizirani sa omotačem od glikobelančevine iz sindbis-virusa
WO2015040063A1 (en) * 2013-09-17 2015-03-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Lentiviral vectors having a mutated integrase protein and uses thereof
EP2878674A1 (en) 2013-11-28 2015-06-03 Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Stable episomes based on non-integrative lentiviral vectors
WO2021062419A1 (en) * 2019-09-29 2021-04-01 Burke John Douglas Novel vectors and uses thereof
US11992542B2 (en) 2019-12-13 2024-05-28 Kristina Kitsos Device and system for providing customized skin color matching sunscreen
KR20240099340A (ko) 2021-10-25 2024-06-28 젠비보, 인크. 치료제 또는 백신 전달을 위한 조성물 및 방법

Similar Documents

Publication Publication Date Title
JP2024541940A5 (https=)
JP6975233B2 (ja) 組換えウイルス、それを含む組成物、及びその使用
Shim et al. Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain
WO2020063370A2 (zh) 免疫组合物及其制备方法与应用
JPH11507808A (ja) 核酸ｒｓウイルスワクチン
WO2021233213A1 (zh) mRNA或mRNA组合物及其制备方法和应用
Bhattacharya et al. Nanodisc-incorporated hemagglutinin provides protective immunity against influenza virus infection
CN114437185B (zh) 冠状病毒三聚体亚单位疫苗及其应用
Khan et al. Adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein
CN113637055B (zh) 一种新型冠状病毒受体结合区糖基化改造抗原及应用
Wang et al. Improving cross-protection against influenza virus using recombinant vaccinia vaccine expressing NP and M2 ectodomain tandem repeats
Park et al. Hemagglutinin virus-like particles incorporated with membrane-bound cytokine adjuvants provide protection against homologous and heterologous influenza virus challenge in aged mice
JP2024532453A (ja) エイズウイルス感染の遺伝子治療用の遺伝子配列構築体
US20230220012A1 (en) High-potency sars coronavirus 2 antigen and vaccine composition comprising same
Bongard et al. Interference of retroviral envelope with vaccine-induced CD8+ T cell responses is relieved by co-administration of cytokine-encoding vectors
WO2022085648A1 (ja) 融合タンパク質及びワクチン
EP3713600B1 (en) Synthetic hemagglutinin as universal vaccine against infection by type b influenza viruses (ibv)
Kawakita et al. ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific CD4+ and CD8+ T-cell responses and neutralizing antibody induction
EP4317176A1 (en) Attenuated reovirus-based vaccine composition and use thereof
Rezaei et al. Antibodies produced toward recombinant RBD and nucleocapsid neutralize SARS-COV-2
WO2022242432A1 (en) Peptide vaccine for virus infection
JP2024532426A (ja) エイズウイルス感染の遺伝子治療用の遺伝子配列構築体
WO2023138333A1 (zh) 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用
JP2024518548A (ja) アミノ酸、ヌクレオチドおよびそれを発現するベクター、ならびにサルベコウイルス感染症の予防におけるそれらの使用
RU2814189C1 (ru) Экспрессионный вектор на основе аденовируса человека 5 серотипа индуцирующий кросс-протективный иммунитет к вирусам гриппа А субтипа H3 и фармацевтическая композиция на его основе.